Overview

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Status:
Recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of response to, or intolerance to prior conventional or advanced therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Genentech, Inc.